Skip to main content
Premium Trial:

Request an Annual Quote

EMD Millipore, Sistemic Developing Stem Cell Technology

NEW YORK (GenomeWeb News) – EMD Millipore today said it is jointly developing a microRNA biomarker-based monitoring methodology with Sistemic for the consistent growth of stem cells in EMD Millipore's Mobius CellReady platform.

The Billerica, Mass.-based Life Science division of Merck KGaA said that the partnership leverages Sistemic's microRNA marker detection capabilities and that the markers may be incorporated into a commercial kit for quality control of stem cells in culture.

Robert Shaw, commercial director of EMD Millipore's Stem Cell Initiative, said in a statement that ensuring the consistency and quality of large-scale culture systems is critical to furthering the use of stem cell products in the clinic, and the partnership with Sistemic "will help us continue our efforts toward the commercialization of stem cell processing."

Financial and other terms were not disclosed.

Glasgow, UK-based Sistemic develops miRNA services and kit-based products for the pharmaceutical, biotechnology, and cell therapy markets.